Fig. 3. INU1-fab-induced platelet consumption and CVT strictly require functional GPIIb/IIIa.

a, Platelet counts (median and interquartile range (IQR)) were monitored using flow cytometry at the indicated time points after INU1-fab (0.5 µg g⁻¹, i.v.) treatment in the depicted mutant or treated wild-type (WT) mice. Heparin (2 U g⁻¹, Ratiopharm, Heparin-Natrium-5000 intraperitoneally (i.p.)), JON/A-F(ab’)₂ (2 µg g⁻¹, i.v.) or p0p/B-fab (2 µg g⁻¹, i.v.) were administered 30 min before INU1-fab. WT n = 7–13, heparin n = 4–16, JON/A n = 5–13, p0p/B n = 5–14, Unc13d^−/− n = 5–6, biologically independent (see source data file for exact numbers for each time point). b, Neurological symptoms of the indicated mice were assessed at different time points using a six-point scoring system (Supplementary Video 9) and depicted as median and IQR: 0, death; 1, severe seizures or circling behavior; 2, post-seizure lethargy; 3, mouse lying ‘exhausted’ on the belly; 4, backward bending of the head and backside; 5, reduced motor control of the hind limbs; 6, seemingly unaffected behavior. WT n = 13, heparin n = 16, JON/A n = 14, p0p/B n = 14, Unc13d^−/− n = 10, biologically independent. c, Mortality following INU1-fab challenge was monitored in the indicated groups. WT n = 14, heparin n = 16, JON/A n = 14, p0p/B n = 14, Unc13d^−/− n = 10, biologically independent. d, SEM (panels on the left-hand side, scale 2 µm) and flow cytometry (panels on the right-hand side) demonstrate that platelets in JON/A-treated mice (2 µg g⁻¹, i.v.) are resting 20 min post INU1-fab (0.5 µg g⁻¹, i.v.) treatment. Depicted are representative images and flow cytometry data of one mouse per group representing n = 3 per group for electron microscopy and n = 8 for flow cytometry (pooled from two independent experiments); FSC indicates forward scatter and SSC side scatter.

Source data